HCW Biologics, a Phase 2 biotech developing novel immunotherapies for cancer, raised $56 million by offering 7.0 million shares at $8, the low end of the range of $8 to $10. The company had originally planned to raise $50 million, but upsized the share offering by 25%. DirectorsIPOs Feed

By

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.